What MRD in AML Partners Are Saying

AbbVie

AbbVie is honored to be part of the Biomarkers Consortium and offers our extensive expertise in acute myeloid leukemia (AML) to help improve the accuracy of current measurable residual disease (MRD) detection approaches and work toward establishing MRD as a validated biomarker. This requires strong collaborations across the consortium, and we are committed to bringing our deep molecular understanding of disease to the betterment of patients living with AML.”

Ian McCaffery, Ph.D.
Vice President of Precision Medicine
AbbVie


Amgen

At Amgen, we are committed to improving outcomes for people with hematologic malignancies by exploring innovative approaches for hopefully eliminating measurable residual disease, or MRD. We are proud to be part of this collaborative project to help develop and validate new methods of detecting and quantifying MRD in acute myeloid leukemia, with the goal of enabling continued innovation that can improve patients’ lives.”

PK Morrow, M.D.
Vice President, Clinical Development
Amgen


AstraZeneca

We are pleased to be part of this unique collaboration that aims to validate novel methods to detect and quantify Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML). Combining the expertise of partners from the broader scientific community we have opportunity to more rapidly advance efforts in MRD, with potential to inform future treatment strategies in AML.”

Raoul Tibes
Executive Medical Director, Global Head Leukemia Strategy & Clinical Development, Oncology R&D
AstraZeneca


Bio-Rad Laboratories Inc., Digital Biology Group

Bio-Rad's participation in the FNIH Biomarkers Consortium provides the pivotal opportunity to better define the complex molecular profiles associated with AML patient monitoring through the power of droplet digital PCR (ddPCR). AML is complex, with a broad range of mutations implicated in disease development and progression. Monitoring mutation profiles with the high sensitivity afforded by advanced molecular tools, such as ddPCR, will increase the likelihood of more focused clinical trials, streamlined drug development, and ultimately, better patient treatments and improved survival rates."

Steve Kulisch
VP Marketing
Bio-Rad Laboratories Inc., Digital Biology Group


Fred Hutchinson Cancer Research Center

This unique partnership of academia, industry, and government affords a unique opportunity to carefully and creatively study MRD. The potential benefits to AML patients are huge."

Jerry Radich
Clinical Research Division, Kurt Enslein Endowed Chair
Fred Hutchinson Cancer Research Center


National Heart, Lung, and Blood Institute (NHLBI)

Acute Myeloid Leukemia (AML) is a blood cancer where long-term cure is achieved for too few. It is now well-established that the remissions observed after treatment, when defined by standard clinical criteria alone, give only an incomplete accounting of the leukemic burden remaining. Research has shown that higher sensitivity methods of detection can identify those patients with measurable residual disease (MRD) who are at an increased risk of death. Technical advances in AML MRD testing in the laboratory have not yet been adequately translated to the clinic but could revolutionize prognostication and monitoring, identify patients who may benefit from clinical trials, and speed the new drug development process. I am delighted to lead this important new multicenter consortium, with the goal of generating a robust foundation of technical and clinical evidence for AML MRD testing. The work of our consortium will represent the important first steps toward harmonized, reproducible, accessible, and clinically relevant testing of MRD in patients suffering from AML.”

Christopher S. Hourigan, DM, DPhil, FACP, FRCP
Chief, Laboratory of Myeloid Malignancies
National Heart, Lung, and Blood Institute
National Institutes of Health


Novartis

We believe that extraordinary scientific innovation starts with partnership, which is why Novartis is proud to support the Biomarkers Consortium in this vital project. The strong collaboration among government, academic institutions and industry will be essential to bringing MRD forward in acute myeloid leukemia, an area of high unmet need.”

Jeff Legos
Executive Vice President, Global Head of Oncology & Hematology Development
Novartis


Sysmex Inostics, Inc.

At Sysmex Inostics, we're elated to join the FNIH and our partners in the Biomarkers Consortium Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) project. We must accelerate the fight to stop patients from succumbing to AML MRD. Currently, it's a flip of a coin if a patient with AML will experience MRD, and mortality rates are unacceptable. With groundbreaking discoveries in oncology and the groundswell of molecular knowledge, it's imperative to bring the best and brightest together now to develop and validate new methods of MRD detection and quantification in AML. At Sysmex Inostics, we are incredibly passionate about the fight against cancer. Since 2008, we have empowered discoveries in oncology by providing investigators with ultra-sensitive liquid biopsy services.”

Shinichi Sato
President and CEO
Sysmex Inostics, Inc.


10x Genomics, Inc.

At 10x Genomics, our mission is to accelerate the mastery of biology to advance human health. We believe in the power of collaboration and are proud to partner with the Foundation for the National Institutes of Health Biomarkers Consortium on this important project to apply new approaches to MRD detection in AML. To deliver on the promise of precision medicine, we need precision tools. We believe single cell analysis is fundamental to illuminating the heterogeneity and dynamics of this complicated disease and transforming patient care."

Ruth De Backer
Chief Business Officer
10x Genomics, Inc.


Thermo Fisher Scientific

There is a critical need for more effective disease monitoring and treatment for patients with Acute Myeloid Leukemia (AML) who are at high risk of relapse. Molecular testing for measurable residual disease (MRD) can help predict potential relapse, but is not widely used for patients with AML due to a lack of accurate, reproducible tests. The FNIH Biomarkers Consortium AML project will play an important role developing new methods of MRD detection to inform future clinical trial design and drug development to help ensure we can match patients with the right therapy, right away. Our participation in the project supports our goal of expanding the use of genomic testing so more patients have access to the benefits of precision medicine.”

Karen E. Nelson
Chief Scientific Officer
Thermo Fisher Scientific


TwinStrand Biosciences, Inc

TwinStrand Biosciences was built upon the need for higher resolution genomic tools to advance cancer research and clinical oncology. We are dedicated to improving patient care in acute myeloid leukemia (AML) as a major part of this mission by enabling more sensitive and specific measurable residual disease (MRD) monitoring. We are honored to partner with the FNIH Biomarkers Consortium to advance precision medicine research and ultimately improve patient outcomes through provision of our ultra-high sensitivity Duplex Sequencing technology."

Jesse Salk, M.D., Ph.D.
CEO, CSO and Founder
TwinStrand Biosciences, Inc